Sanofi and Advent International have finalised negotiations for the acquisition of Zentiva — Sanofi’s European generics business — with both companies signing a Share Purchase Agreement worth €1.9 billion.
Negotiations
This purchase agreement is a critical step towards closure of the deal and transfer of Zentiva to Advent, which is expected to complete in the fourth quarter of this year (2018). The transaction still remains subject to the approval of the regulatory authorities. Exclusive talks surrounding the acquisition were entered by both companies earlier this year (April 2018).
Zentiva provides access to a broad generics portfolio across Europe and covers a multitude of therapeutic areas. It is headquartered in Prague and currently reaches more than 40 million patients in 25 European countries. With its pan-European commercial footprint, Zentiva is one of the largest generics manufacturers in the region. Additionally, it has flexible manufacturing facilities in Prague and Bucharest that produce and distribute more than 350 million packs each year.
Advent Internationalis a global private equity investor, which has invested in over 335 private equity transactions in 41 countries. At its latest valuation it has €33 billion in assets under management.
